Loading…
Eli Lilly will invest $400 million to expand biomanufacturing capacity at its Lilly Technology Center campus in Indianapolis, Indiana. The investment will support production of diabetes medicines, including insulins and Trulicity, with capacity and technology upgrades.
CMIT has signed a six-year contract with Eli Lilly/AVID to produce F-18 labeled AV-1451 PET radiopharmaceutical for early detection of Alzheimer's disease at its Southern Isotopes facility in Shreveport.
| Site | Largest | Latest |
|---|---|---|
| Indianapolis, United States | $400.0M | 2019-11-20 |